Recent Transactions

15-Jun-16
$414 million
United States flag
Target: 

Aegerion Pharmaceuticals

Canada flag
Acquiror: 
QLT Inc.

Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization

11-Jun-16
$350 million
Israel flag
Target: 

US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Dr. Reddy’s Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories

04-May-16
$NA
United States flag
Target: 

Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

United States flag
Acquiror: 
Ligand Pharmaceuticals

Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

22-Apr-16
$NA
Brazil flag
Target: 

Elavon do Brasil

Brazil flag
Acquiror: 
Stone Pagamentos

Advised Minneapolis-based US Bancorp, the fifth largest commercial bank in the United States, and the parent company of Elavon, Inc., in the sale of its 50.1 percent majority stake in São Paulo-based, Elavon do Brasil to Stone Pagamentos, a local market, privately-held merchant acquirer.

19-Apr-16
$NA
United States flag
Target: 

Total Care Medicaid Plan

United States flag
Acquiror: 
Molina Healthcare, Inc.

Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan

07-Mar-16
$NA
Germany flag
Target: 

Boehringer Ingelheim

United States flag
Acquiror: 
AbbVie

Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.

26-Feb-16
$NA
Brazil flag
Target: 

Policard

France flag
Acquiror: 
Groupe Up

Advised Policard, one of the largest electronic payment companies in Brazil, on the combination of its business with the Brazilian operations of Groupe Up, one of the leading employee benefits, public, social and loyalty programs providers in the world

02-Feb-16
$314 million
Greece flag
Target: 

11 Private Equity Fund Positions Managed by NBGI Private Equity and Team’s Spinout

U.S.A., U.K. flags
Acquiror: 
Deutsche Bank Private Equity and Goldman Sachs Asset Management

Advised the National Bank of Greece SA, the leading bank in Greece by deposits and total assets, on the disposal of 100% of its interests in eleven funds managed by NBGI Private Equity. The management responsibility of the funds and underlying investments will continue to be performed by the current management team along with other persons appointed by the buyers, under a new management vehicle created expressly for this purpose

15-Dec-15
$4.3 billion
United States flag
Target: 

Heartland Payment Systems, Inc.

United States flag
Acquiror: 
Global Payments Inc.

Advised Heartland Payment Systems, Inc., one of the nation’s largest payment companies, on its sale to Global Payments Inc., a leading worldwide provider of payment technology services

01-Dec-15
$NA
United Kingdom flag
Target: 

Allied Healthcare

Germany flag
Acquiror: 
AURELIUS Investments

Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments

29-Oct-15
$275 million
United States flag
Target: 

Aesynt, Inc.

United States flag
Acquiror: 
Omnicell, Inc.

Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems

28-Sep-15
$NA
United States flag
Target: 

Alcoa Inc.

flag not available

Advised Alcoa Inc. on its separation into two independent, publicly-traded companies

10-Sep-15
$NA
United States flag
Target: 

International Medical Group, Inc.

United States flag
Acquiror: 
ABRY Partners

Advised International Medical Group, Inc., a leader in the global insurance and assistance services market, on its sale to ABRY Partners

27-Jul-15
$40.5 billion
Ireland flag
Target: 

Allergan Generics

Israel flag
Acquiror: 
Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

06-Jul-15
$910 million
United States flag
Target: 

Altegra Health, Inc.

United States flag
Acquiror: 
Emdeon Inc.

Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare

02-Jun-15
$NA
United Kingdom flag
Target: 

Portfolio of GlaxoSmithKline plc consumer and OTC brands

United States flag
Acquiror: 
Perrigo Company plc

Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc

26-May-15
$2.2 billion
United States flag
Target: 

Nordstrom, Inc. (Credit Card Assets)

U.S.A., Canada flags
Acquiror: 
The Toronto-Dominion Bank Group

Advised The Toronto-Dominion Bank Group on its acquisition of Nordstrom, Inc.’s credit card assets

09-Mar-15
$1.5 billion
United States flag
Target: 

RTI International Metals, Inc

United States flag
Acquiror: 
Alcoa Inc.

Advised Alcoa Inc. on the acquisition of RTI International Metals, Inc., a leading producer and global supplier of titanium mill products and a manufacturer of fabricated titanium and specialty metal components, principally for the commercial aerospace and defense sectors

23-Feb-15
$NA
United States flag
Target: 

Softcard (JVL Ventures, LLC)

United States flag
Acquiror: 
Google Inc.

Advised Softcard, a joint venture of AT&T, Verizon and T-Mobile focused on mobile payments and commerce, on the sale of certain assets to Google

20-Feb-15
$800 million
United States flag
Target: 

GFI Group Inc.

United States flag
Acquiror: 
BGC Partners, Inc.

Advised the Special Committee of GFI Group Inc. on its sale to BGC Partners, Inc.

15-Dec-14
$NA
Germany flag
Target: 

TITAL GmbH

United States flag
Acquiror: 
Alcoa Inc.

Advised Alcoa Inc. on the acquisition of TITAL GmbH, a privately-held German manufacturer of aluminum and titanium castings predominately for the aerospace and defense end markets

03-Sep-14
$300 million
United States flag
Target: 

Voya Financial, Inc.

flag not available

Advised the Independent Committee of the Board of Directors of Voya Financial, Inc. in connection with Voya Financial, Inc.’s repurchase of 7.7mm shares (aggregate repurchase of $300mm) from ING Groep N.V.

11-Aug-14
$NA
United States flag
Target: 

MannKind Corporation

France flag
Acquiror: 
Sanofi

Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.

05-Aug-14
$1.3 billion
U.S.A., Germany flags
Target: 

Siemens Health Services

United States flag
Acquiror: 
Cerner Corporation

Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.

28-Jul-14
$90 million
Australia flag
Target: 

Clinuvel Pharmaceuticals Limited

United States flag
Acquiror: 
Retrophin, Inc.

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases

Pages

show all